The Centre for Cellular and Molecular Platforms (C-CAMP) announced on Tuesday that it has strengthened its collaboration with American laboratory technology giant Agilent Technologies. This expanded partnership provides a significantly broader range of Indian researchers access to some of the world's most advanced drug-testing equipment without requiring them to purchase the instruments themselves.
Democratizing Access to High-Cost Scientific Instruments
Think of this arrangement as a library, but for multimillion-dollar scientific instruments. The importance of this collaboration stems from the fact that cutting-edge drug development has long been hindered by the high cost of specialist equipment. Small biotech startups and university researchers with promising ideas but limited budgets traditionally had to forgo such tools or seek them abroad. This partnership changes that dynamic, allowing researchers to book time on advanced machines housed at C-CAMP's Bengaluru facility.
Early Success with Liraglutide
The collaboration has already yielded tangible results. In its initial phase, the partnership enabled Indian scientists to fully characterize Liraglutide—a drug widely used to treat diabetes and obesity—using equipment provided by Agilent. The work met international regulatory standards, a significant achievement for a molecule developed and tested entirely within India.
Expanding to Complex Biological Medicines
The expanded tie-up will now cover a broader range of drug types, including complex biological medicines that are increasingly at the forefront of treatments for cancer, rare diseases, and infectious conditions. To kick off the new phase, the two organizations will conduct a training program for scientists from startups and industry, providing hands-on skills with the equipment.
Leadership Perspectives
Taslimarif Saiyed, CEO of C-CAMP, emphasized that the partnership is about making world-class science more democratic. He stated, "Such collaborations will play a key role in enabling technology development and accelerating science-led innovation." Nandakumar Kalathil, who heads Agilent's India operations, highlighted India's strategic importance to the company. "India is a strategic priority for Agilent, and partnerships like this are central to how we expand access to critical scientific capabilities," he said.
This initiative is expected to accelerate drug discovery and development in India, particularly for small and medium-sized enterprises and academic institutions that lack the capital to invest in expensive laboratory equipment. By providing access to state-of-the-art analytical tools, the partnership aims to foster a more vibrant ecosystem for pharmaceutical innovation in the country.
